Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi
07:11am, Monday, 10'th Jul 2023
Stocks often react differently from the way you think they might. That happened on July 7 as shares of Biogen Inc. NASDAQ: BIIB swooned 2.88% in heavy trading volume following news of full regulatory
Biogen And Alzheimer's Disease: Too Early To Celebrate
11:52pm, Sunday, 09'th Jul 2023
The FDA has granted full approval to Biogen and Eisai's anti-amyloid antibody drug Leqembi, but there is skepticism about its efficacy and safety. The approval led to a drop in Biogen's stock, in part
Biogen Just Reached a Big Milestone. Why Isn't the Stock Rising?
06:00am, Sunday, 09'th Jul 2023
The FDA just approved Biogen's new Alzheimer's treatment Leqembi. This could become the company's next billion-dollar product -- and kickstart growth.
Medicare will pay for Alzheimer's drug Leqembi. What patients and doctors should know
07:00am, Saturday, 08'th Jul 2023
Patients with early Alzheimer's disease could still pay more than $5,000 in out-of-pocket costs for Leqembi even with Medicare coverage.
Dow Jones Today: Index Falls After Soft Jobs Report
05:00pm, Friday, 07'th Jul 2023
Job creation came in lower than expected, and investors are still worried about higher interest rates, sending the Dow lower by about 190 points.
Three-Stock Lunch: Meta, Biogen and Levi Strauss
03:33pm, Friday, 07'th Jul 2023
Gina Sanchez, chief market strategist at Lido Advisors, joins ‘Power Lunch' to discuss her thoughts on three stocks: Meta, Biogen and Levi Strauss.
FDA approves Biogen's Leqembi: the Alzheimer's drug will ‘surprise to the upside'
02:32pm, Friday, 07'th Jul 2023
Biogen Inc (NASDAQ: BIIB) is trading down this morning even though the Food and Drug Administration awarded full approval to its Alzheimer's drug – Leqembi.
Sales of Alzheimer's drug Leqembi may be slow initially but could pick up in 2024
01:59pm, Friday, 07'th Jul 2023
Analysts believe the Medicare registry requirement and new guidance on Leqembi's prescription label could potentially weigh on sales in the near term.
Biogen's Alzheimer's Drug Rollout Could Be Slow
01:17pm, Friday, 07'th Jul 2023
Biogen has said it doesn't expect to clear a profit on Alzheimer's treatment Leqembi, which was approved by the FDA Thursday, until late 2024.
Markets Mixed Midday as Job Growth Slows
12:25pm, Friday, 07'th Jul 2023
U.S. equities were mixed at midday on Friday, July 7, 2023 after the government's June jobs report showed job creation slowed.
Eisai-Biogen's Alzheimer's treatment drug receives FDA approval
11:15am, Friday, 07'th Jul 2023
Shares of Biogen and Eisai are lower amid news of label updates to the FDA officially approved the Alzheimer's treatment drug Leqembi. Yahoo Finance Live breaks down the story.
Demand for Biogen's new Alzheimer's drug will surprise to the upside, says Piper Sandler analyst
11:06am, Friday, 07'th Jul 2023
Christopher Raymond, Piper Sandler, joins 'Squawk on the Street' to discuss the market's reaction to Biogen's FDA approval, what demand will look like for Biogen's new drug and the serious side effect
Will Watershed Moment For Alzheimer's Propel Biogen Stock Higher?
10:20am, Friday, 07'th Jul 2023
Esai and Biogen's Alzheimer's Disease therapeutic, Leqembi, received full FDA approval on July 6th. Full approval likely means at least $100s millions/annual revenue since Medicare will reimbursement
BIIB Stock Alert: What to Know as FDA Approves Biogen's Alzheimer's Drug
09:57am, Friday, 07'th Jul 2023
Biogen (NASDAQ: BIIB ) stock is in the news Friday after the company got approval from the FDA for its Alzheimer's drug. This covers the traditional approval of LEQEMBI.
5 Things to Know Before Markets Open
07:50am, Friday, 07'th Jul 2023
The government's latest jobs report is expected to show continued strength in the labor market and the FDA gives approval to a new Alzheimer's disease treatment. Here's what investors need to know tod
